SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster ...
Advancement of Fast Skeletal Muscle Troponin Activator Expands Pipeline of Muscle-Directed Drug Candidates SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated ...
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today positive results from the first cohort, or Part A, of a continuing Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback